

Evidence to Recommendation Table 2

Question: Are there novel approaches to RIG (-sparing) injection vs current practice as part of PEP for category III exposed patients? Such as (a) discontinuation of calculation of RIG dose needed according to body weight and/or (b) RIG into or around the bite wound(s) only without additional administration of remaining RIG to other sites distant to the wound?

Population: Those eligible for RIG (Category III exposed individuals and immuno-compromised category II exposed

Intervention: Dose-sparing use of RIG:

- a. RIG volume calculation based on factors other than patient body weight
- b. RIG administration to wound area without remaining RIG injection at sites distant to the wound

Comparison(s): Current recommendations:

- a. RIG volume calculation based on body weight: 20 IU/kg body weight for hRIG and 40 IU/kg body weight for eRIG
- b. RIG administration into or around the wound sites with remaining RIG dose injected intramuscularly at a site distant from the site of vaccine administration

Outcome: Sustained or increased patient survival; more efficient use of RIG; improved cost-effectiveness

Background:

The high cost (hRIG 40\$, eRIG 30\$ per vial, for an adult 3-4 vials of eRIG are needed for PEP), low availability and supply, batch to batch variation affecting efficacy, uncertain quality (no WHO prequalification process), short shelf-life and correct administration of RIG are barriers to implementing the standard set by WHO for PEP. This represents a missed opportunity for PEP. There is evidence to suggest that simplifying WHO recommendations to allow for the use of less RIG could be equally effective in the prevention of rabies. RIG is often a barrier for attaining public health impact because of a hesitation to use vaccine without RIG and therefore manufacturers and clinicians often do not want to make vaccines available without RIG, which means no PEP at all. The dose sparing use of RIG based on new evidence available is important issue for consideration. The individuals in rabies-endemic settings most often affected are those who can least access and afford PEP. Additionally, RIG is in scarce availability, compared to the other components of the PEP regimen, so its efficient use is important for ensuring maximal availability to the patients bearing the highest risk of rabies infection.

	CRITERIA	JUDGEMENTS				RESEARCH EVIDENCE	ADDITIONAL INFO
PROBLEM	Is the problem a public health priority?	No	Uncertain	Yes	Varies by setting	RIG is life-saving particularly in severe rabies exposures when administered within 7 days following the first dose of vaccination. Only a small percentage of severe suspect rabid animal bite victims can currently access RIG due to its high cost and low availability. Public	Rabies causes approximately 59,000 deaths annually and is a public health problem in more than 150 countries
		<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>		

				health authorities’ budget for procurement of RIG is in most cases very limited or even absent. Worldwide, only 2% of individuals requiring RIG receive it. Conversely, in other settings there may be a tendency of overuse RIG. Paying for vaccine and RIG can cause catastrophic out of pocket expenses to individuals in rabies-endemic areas (in some settings equivalent to more than a month’s salary).	worldwide. Moreover, children under 15 years of age most frequently suffer from severe rabies exposures. As rabies is a neglected zoonotic disease, most deaths occur in poor and marginalized communities in Asia and Africa.		
BENEFITS & HARMS OF THE OPTIONS	<u>Benefits of the intervention</u> Are the desirable anticipated effects large?	No <input type="checkbox"/>	Uncertain <input type="checkbox"/>	Yes <input checked="" type="checkbox"/>	Varies by setting <input type="checkbox"/>	<p>The beneficial effects of this intervention include (a) Improved access to and more efficient use of life-saving RIG ; (b) more equitable use of RIG, and (c) cost-savings for both individuals and public health sector.</p> <p>The beneficial effects of this intervention are large per individual. As rabies is invariably fatal, RIG corresponds directly to lives saved, particularly in case of severe exposures. Moreover, as rabies PEP is only administered to those potentially exposed to the rabies virus, there is a high impact.</p>	Offering this intervention, will particularly benefit the subgroups of rabies-exposed children and people living in marginalized and low-resource communities.

	<u>Harms of the intervention</u> Are the undesirable anticipated effects small?	<i>No</i> <input type="checkbox"/>	<i>Uncertain</i> <input type="checkbox"/>	<i>Yes</i> <input checked="" type="checkbox"/>	<i>Varies by setting</i> <input type="checkbox"/>	Due to inadequate training and non-standardized volume of administration, clinician decision is needed and adequate training will be required. Clinicians are averse to infiltrating wounds with RIG. Administration of RIG into small wound spaces (<i>e.g.</i> finger tips, toes, ears, noses) is limited and may create compartment syndrome and may not achieve a sufficient dose of virus neutralizing antibodies.	The baseline risk for harm is similar across subgroups.
	Balance between benefits and harms	<i>No</i> <input type="checkbox"/>	<i>Uncertain</i> <input type="checkbox"/>	<i>Yes</i> <input checked="" type="checkbox"/>	<i>Varies by setting</i> <input type="checkbox"/>	Increased affordability, availability and accessibility of RIG in low-resource settings saves lives. Experimental studies in the animal model show that neutralization by RIG occurs at the site of infection and antibodies injected intramuscularly stay at the injection site. Theoretical calculations carried on patient data from Cambodia show that the remaining RIG dose (maximum dose based on body weight) injected distant from the wound site is unlikely to produce adequate levels of circulating virus neutralizing antibody titers > 0.5 IU/ml throughout the body, but maybe provide additional safety in severe exposures or when small bite	Training of clinicians in risk assessment and correct post-exposure administration is needed.

			wounds are overlooked.	
	What is the overall quality of this evidence for the critical outcomes?	<div>Effectiveness of the intervention</div> <div><div>No included studies</div><div>Very low</div><div>Low</div><div>Moderate</div><div>High</div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div> <div>Safety of the intervention</div> <div><div>No included studies</div><div>Very low</div><div>Low</div><div>Moderate</div><div>High</div><div><input type="checkbox"/></div><div><input type="checkbox"/></div><div><input checked="" type="checkbox"/></div><div><input type="checkbox"/></div><div><input type="checkbox"/></div></div>	<div>There are only a few observational studies on this subject. As rabies is a fatal disease, conducting randomized controlled trials presents ethical and logistical challenges and therefore would not be feasible.</div>	

VALUES & PREFERENCES	How certain is the relative importance of the desirable and undesirable outcomes?	<div> <div>Important uncertainty or variability</div> <input type="checkbox"/> </div> <div> <div>Possibly important uncertainty or variability</div> <input type="checkbox"/> </div> <div> <div>Probably no important uncertainty or variability</div> <input checked="" type="checkbox"/> </div> <div> <div>No important uncertainty or variability</div> <input type="checkbox"/> </div> <div> <div>No known undesirable outcomes</div> <input type="checkbox"/> </div>	There are a limited number of studies on the intervention and large-scale experience has been collected mainly from one country or in the experimental animal model. Not all field studies consider the confirmation of the rabies status of the biting animal to determine the certainty of rabies exposure. As rabies is a fatal disease, any intervention improving accessibility and affordability of RIG will outweigh undesirable outcomes or levels of uncertainty due to the quality of the studies.	
	Values and preferences of the target population: Are the desirable effects large relative to undesirable effects?	<div>No</div> <input type="checkbox"/> <div>Probably No</div> <input type="checkbox"/> <div>Uncertain</div> <input type="checkbox"/> <div>Probably Yes</div> <input type="checkbox"/> <div>Yes</div> <input checked="" type="checkbox"/> <div>Varies</div> <input type="checkbox"/>	<p>The value of this intervention lies in life-, dose and cost-saving use of RIG for both the public health sector and the individual. Saved doses of RIG would be available for additional patients.</p> <p>RIG is often a barrier for attaining public health impact because of a hesitation to use vaccine without RIG and therefore manufacturers and clinicians often do not want to make vaccines available without RIG, which means no PEP at all.</p>	Most rabies deaths occur in children in low-resource settings.
RESOURCE USE	Are the resources required small?	<div>No</div> <div>Uncertain</div> <div>Yes</div> <div>Varies</div>	Resources additional to the current RIG recommendations are not required for this intervention . It will decrease the costs required for RIG	The lower cost per patient may favor an increased uptake

		<input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> <input type="checkbox"/>	<p>purchase by both individuals (out of pocket expenses) or health care systems (if subsidized or free of charge to the patient).</p>	<p>by governments resulting in better forecasting and increased affordability.</p>
	Cost-effectiveness	<i>No</i> <input type="checkbox"/> <i>Uncertain</i> <input type="checkbox"/> <i>Yes</i> <input checked="" type="checkbox"/> <i>Varies</i> <input type="checkbox"/>	<p>This intervention improves cost-effectiveness of PEP as a reduction of 60% to 80% in RIG dose volume can be obtained by the intervention compared to previous recommendations. Modelling results show savings of up to 40% of RIG volume, rapidly increasing with patient throughput as vials can be fractionated more effectively</p>	
EQUITY	What would be the impact on health inequities?	<i>Increased</i> <input type="checkbox"/> <i>Uncertain</i> <input type="checkbox"/> <i>Reduced</i> <input checked="" type="checkbox"/> <i>Varies</i> <input type="checkbox"/>	<p>Health inequity would be reduced through this intervention, as more people would have access to RIG and it would be a feasible intervention at decentralized healthcare facilities (in many countries rabies biologics are only available at central level or the capital)</p>	

ACCEPTABILITY	Which option is acceptable to key stakeholders (Ministries of Health, Immunization Managers)?	<i>Intervention</i> <input type="checkbox"/>	<i>Comparison</i> <input type="checkbox"/>	<i>Both</i> <input checked="" type="checkbox"/>	<i>Neither</i> <input type="checkbox"/>	<i>Unclear</i> <input type="checkbox"/>	As the intervention is highly cost-effective, the acceptability will be high for stakeholders in low-resource settings as it will save additional lives without increasing costs, since less RIG will be needed on average per person	
	Which option is acceptable to target group?	<i>Intervention</i> <input checked="" type="checkbox"/>	<i>Comparison</i> <input type="checkbox"/>	<i>Both</i> <input type="checkbox"/>	<i>Neither</i> <input type="checkbox"/>	<i>Unclear</i> <input type="checkbox"/>	<p>The majority of the target group consists of rural or marginalized populations who have limited access to health care systems and often face resource constraints to pay for RIG and vaccines.</p> <p>High-resource countries where RIG is available in sufficient quantity and affordable to individuals have the option to maintain the original policy.</p>	

FEASIBILITY	Is the intervention feasible to implement?	<i>No</i> <input type="checkbox"/>	<i>Probably No</i> <input type="checkbox"/>	<i>Uncertain</i> <input type="checkbox"/>	<i>Probably Yes</i> <input type="checkbox"/>	<i>Yes</i> <input checked="" type="checkbox"/>	<i>Varies</i> <input type="checkbox"/>	<p>Data show that continued education of healthcare providers is needed to improve correct RIG administration, regardless of the intervention or comparator chosen. Cold-chain and delivery mechanisms are equally challenging for both options.</p> <p>Shortages in supply are very frequent, at both, central and decentralized levels. Thus, the intervention is likely to reduce costs and resolve some of the supply issues resulting in timely and affordable care to patients.</p>	<p>This intervention would improve accessibility to RIG and would be cost-saving to individuals and health care systems. This intervention would be particularly feasible and beneficial in low-resource settings .</p>	
	Balance of consequences	<p>Undesirable consequences <i>clearly outweigh</i> desirable consequences in most settings</p> <input type="checkbox"/>	<p>Undesirable consequences <i>probably outweigh</i> desirable consequences in most settings</p> <input type="checkbox"/>			<p>The balance between desirable and undesirable consequences <i>is closely balanced or uncertain</i></p> <input type="checkbox"/>	<p>Desirable consequences <i>probably outweigh</i> undesirable consequences in most settings</p> <input checked="" type="checkbox"/>	<p>Desirable consequences <i>clearly outweigh</i> undesirable consequences in most settings</p> <input type="checkbox"/>		
	Type of recommendation	<p>We recommend the intervention</p> <input checked="" type="checkbox"/>	<p>We suggest considering recommendation of the intervention</p> <input type="checkbox"/> Only in the context of rigorous research <input type="checkbox"/> Only with targeted monitoring and evaluation <input checked="" type="checkbox"/> Only in specific contexts or specific populations			<p>We recommend the comparison</p> <input type="checkbox"/>	<p>We recommend against the intervention and the comparison</p> <input type="checkbox"/>			

Recommendation (text)	<p>1. The RIG dose is calculated by weight, for hRIG at 20 IU/kg, and for purified eRIG or F(ab')₂ products at 40 IU/kg body weight.</p> <p>2. After calculating the RIG dose, only the amount of RIG necessary for infiltrating into and around the wound is administered, as much as anatomically possible (e.g. to avoid compartment syndrome). The maximum benefits of RIG are gained when administered directly into the wound. For large and multiple wounds, the RIG dose can be diluted with physiological buffered saline to ensure greater wound coverage</p> <p>3. The remainder of the calculated maximum dose of RIG does not need to be injected IM at a distance from the wound. The dose can be fractionated in smaller, individual syringes to be used for other patients, but this requires aseptic retention. In settings where RIG is of low availability, the relative benefits of IM RIG injection distant to the wound should be weighed against the possibility of providing the remaining RIG to other patients, to confer maximum public health benefit.</p>
Implementation considerations	<p>General training of healthcare personnel especially those managing injuries/emergencies, should include management of rabies exposures and PEP including RIG administration. Additionally, there should be training on safe fractionating of RIG vials to avoid contamination of open vials shared between several patients.</p>
Monitoring and evaluation	<p>The intervention is already being implemented in India and will be in other settings. This intervention should be continued to be evaluated.</p> <p>Due to varying quality of available RIG products and no pre-qualification process rigorous M&E of RIG use and any adverse effects should be conducted.</p>
Research priorities	<p>1.</p>